Mylan Pursues ‘Market First’ Playbook, Partners Lupin For Enbrel Biosimilar

 
• By Anju Ghangurde
  
Game changer
MYLAN IS KEEN TO GET ITS MARKET TIMING RIGHT FOR KEY BIOSIMILARS

More from Business

More from Generics Bulletin